Peru vs Singapore: Access to anti-retroviral drugs, female
Peru
86.0%
in 2024
Singapore
84.0%
in 2023
Peru rank
47th
Singapore rank
50th
Access to anti-retroviral drugs, female over time
- Peru
- Singapore
How they compare
Peru currently reports 86.0% against 84.0% in Singapore, a difference of 2.0%.
The two have swapped places 4 times across 24 shared years of data; in 2000 it was Singapore ahead.
Peru ranks 47th and Singapore ranks 50th of 141 countries.
Singapore has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Peru | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 12.3% | 19.9% | 7.6% | Singapore |
| 2010s | 59.6% | 59.6% | 0.0% | — |
| 2020s | 76.0% | 80.8% | 4.8% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Peru or Singapore?
- Peru, at 86.0% against 84.0% in Singapore as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Peru and Singapore?
- 2.0%, with Peru ahead.
- How many years of comparable data are there for Peru and Singapore?
- 24 years are reported by both, from 2000 to 2023.
- How do Peru and Singapore rank globally for access to anti-retroviral drugs, female?
- Peru ranks 47th and Singapore ranks 50th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.